S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
The 3-Stock Retirement Blueprint (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
The 3-Stock Retirement Blueprint (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
The 3-Stock Retirement Blueprint (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
The 3-Stock Retirement Blueprint (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief

Is Sanofi A Buy, Despite Recent Stumbles?

Is Sanofi A Buy, Despite Recent Stumbles? Pharmaceutical stocks are frequently subject to whiplash trade, and that’s evident now with sharp moves lower in names such as Sanofi (NASDAQ: SNY), GSK (NYSE: GSK), and Teva Pharmaceuticals (NYSE: TEVA)

Price swings in that industry are often determined by the results of clinical trials or other studies. That’s exactly what happened in the case of Sanofi, which offers a lesson in the risks inherent in pharma stocks, even among well-established large caps.

Sanofi shares gapped down 5.87% Wednesday, closing at $42.18, on news that the company would end two studies of potential breast cancer treatment amcenestrant. The studies were halted following an interim analysis indicating that the drug, used in tandem with Pfizer's (NYSE: PFE) breast cancer drug Ibrance, “did not meet the prespecified boundary for continuation in comparison with the control arm,” according to a Sanofi news release.  

"While we are disappointed by this outcome, our research will further the scientific understanding of endocrine therapies in people with breast cancer," said Sanofi's global head of research and development, John Reed, in the release. 

Does Sanofi Still Seem Promising? 

Not all analysts believe the stock is doomed, however. For example, Morningstar’s Damien Conover wrote, “[D]rug development is risky, and failures are common. We do not see these pipeline setbacks as overly concerning, and we continue to believe Sanofi will be able to develop the next generation of drugs to offset eventual patent losses, which is a key factor supporting its wide moat. Also, the limited patent losses over the next several years also provide time for Sanofi to refill its late-stage pipeline with several early-stage drugs that look encouraging.”


MarketBeat analyst ratings show the consensus on Sanofi remains a “moderate buy.”

Wednesday’s gap-down came just one week after the stock plummeted 7.11% in advance of a trial surrounding heartburn treatment Zantac. Sanofi, along with Pfizer and GSK and others, sold the drug for periods of time before the FDA ordered Zantac pulled from the market in April 2020. 

The stock is down 16.44% in the past month and 12.94% year-to-date. 

Sanofi shares opened lower on Thursday. 

GSK shares were also hammered on the Zantac news. The stock fell 4.32% on August 10 and another 6.71% the next day. 

Plaintiffs have brought thousands of suits against drug companies that sold Zantac, claiming various types of cancer resulted from taking the medication. In the first trial, which was scheduled to begin in Illinois next week, the plaintiff dropped his case, saying he was too ill to proceed. However, he has the right to refile his case within the next year. 
Is Sanofi A Buy, Despite Recent Stumbles?

Lagging Broader Healthcare Sector

Like Sanofi, GSK was already tumbling ahead of the Zantac news. Shares are down 16.41% year-to-date. 

Both Sanofi and GSK are based outside the U.S., meaning they are not tracked by the S&P 500. However, because the S&P large-cap healthcare sector is where they would otherwise be indexed, if they were domestic companies, it’s a valid comparison. 

The healthcare sector is down just 4.94% year-to-date. That much better sector performance is driven by big components like UnitedHealth Group (NYSE: UNH) and Eli Lilly (NYSE: LLY), both of which boast strong 2022 gains. 

Meanwhile, Israel-based Teva Pharmaceuticals, which, at $11.54 billion is on the lower end of the large-cap classification, shed 10.63% this week, but still boasts a year-to-date gain of 24.97%. 

Shares fell 9.25% Wednesday, closing at $10.01, following the company’s voluntary recall of two lots of hypertension medication Matzim LA. Testing revealed that the tablets were not dissolving properly. 

More Companies Involved With Zantac

Teva is also connected to the Zantac case. According to Bloomberg reports this week, Teva and other generic drug makers, including Perrigo (NYSE: PRGO) and Dr. Reddy’s (NYSE: RDY) agreed to a combined settlement totaling $500,000.

Perrigo and Dr. Reddy’s are both trading lower this week. 

As you can see from all the recent news-driven declines in pharma stocks, the entire industry is particularly susceptible to developments surrounding clinical trials, lawsuits and other events. It’s always incumbent upon investors to understand the industry risks inherent in any stock, but that’s especially true when it comes to pharma, when big news could break at any time that could send your stock tumbling. 

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Sanofi (SNY)
2.978 of 5 stars
$38.02+0.1%3.31%12.63Moderate Buy$105.38
GSK (GSK)
2.2879 of 5 stars
$29.43+0.2%5.20%9.75HoldN/A
Teva Pharmaceutical Industries (TEVA)
1.9066 of 5 stars
$8.07+3.2%N/A-8.49Hold$10.67
UnitedHealth Group (UNH)
3.1282 of 5 stars
$505.04-0.7%1.31%26.37Moderate Buy$586.40
Eli Lilly and (LLY)
2.706 of 5 stars
$323.35-2.0%1.21%51.57Moderate Buy$333.82
Perrigo (PRGO)
2.784 of 5 stars
$35.66-0.8%2.92%-50.94Buy$51.67
Dr. Reddy's Laboratories (RDY)
2.4074 of 5 stars
$52.34+0.2%0.61%22.37Buy$69.00
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Sanofi right now?

Before you consider Sanofi, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.

While Sanofi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Kate Stalter

About Kate Stalter

Contributing Author: Retirement, Asset Allocation, and Tax Strategies

Kate Stalter is a Series 65-licensed asset manager, with more than two decades of experience in various areas of financial services. As an investment advisor and financial planner, Kate personally manages client portfolios, with a focus on successful retirement, including asset allocation, income generation and tax strategies. Kate also serves as a capital-markets contributor at Forbes.com, and is an expert columnist for the investment advisory channel at U.S. News & World Report.
Contact Kate Stalter via email at stalterkate@gmail.com.
Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC

Axel Merk, President and CIO of Merk Investments has three very different stocks he frames within the current market and economic conditions.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.